格隆汇3月3日丨百奥泰(688177.SH)公布,公司于近日收到了英国药品和健康产品管理局签发的关于Usymro(BAT2206,乌司奴单抗注射液)上市批准通知。BAT2206 是百奥泰根据中国 NMPA、美国 FDA、欧洲EMA 生物类似药相关指导原则开发的乌司奴单抗注射液,乌司奴单抗是一款靶向白细胞介素IL-12和 IL-23 共有的 p40 亚基的全人源单克隆抗体。IL-12 和IL-23 ...
Source Link格隆汇3月3日丨百奥泰(688177.SH)公布,公司于近日收到了英国药品和健康产品管理局签发的关于Usymro(BAT2206,乌司奴单抗注射液)上市批准通知。BAT2206 是百奥泰根据中国 NMPA、美国 FDA、欧洲EMA 生物类似药相关指导原则开发的乌司奴单抗注射液,乌司奴单抗是一款靶向白细胞介素IL-12和 IL-23 共有的 p40 亚基的全人源单克隆抗体。IL-12 和IL-23 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.